PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 16, 2025Molecules29 citationsOpen Access

Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer’s Disease

View Full Paper
AAA AsimMJMichał K. JastrzębskiAKAgnieszka A. Kaczor

Key Points

  • Dual inhibitors of acetylcholinesterase and monoamine oxidase B may improve treatment for Alzheimer's disease.
  • The classification of dual inhibitors is based on their chemical structure and mechanisms of action.
  • Computer-aided design strategies enhance the development of effective dual inhibitors targeting AD pathology.
  • Understanding structure–activity relationships helps in optimizing compounds for better therapeutic outcomes in neurodegenerative disorders.

Abstract

Alzheimer’s disease (AD) is a multi-factorial neurodegenerative disease with a complex pathomechanism that can be best treated with multi-target medications. Among the possible molecular targets involved in AD, acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) are well recognized because they control the neurotransmitters responsible for memory processes. This review discusses the current understanding of AD pathology, recent advances in AD treatment, and recent reports in the field of dual AChE/MAO-B inhibitors for treating AD. We provide a classification of dual inhibitors based on their chemical structure and describe active compounds belonging to, i.a., chalcones, coumarins, chromones, imines, and hydrazones. Special emphasis is given to the computer-aided strategies of dual inhibitors design, their structure–activity relationships, and their interactions with the molecular targets at the molecular level.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Asim et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8cca52https://doi.org/10.3390/molecules30142975
Ask AI
Helpful
Bookmark
Share
View Full Paper